Brinks, H. L., Rohde, D., Voelkers, M., Qiu, G., Pleger, S. T., Herzog, N., … Most, P. (2011). S100A1 GENETICALLY TARGETED THERAPY REVERSES DYSFUNCTION OF HUMAN FAILING MYOCARDIUM. In Journal of the American College of Cardiology (Vol. 57, pp. E188–E188). Elsevier BV. https://doi.org/10.1016/s0735-1097(11)60188-5

Brinks, Henriette L., David Rohde, Mirko Voelkers, Gang Qiu, Sven T. Pleger, Nicole Herzog, Joseph Rabinowitz, et al. “S100A1 GENETICALLY TARGETED THERAPY REVERSES DYSFUNCTION OF HUMAN FAILING MYOCARDIUM.” In Journal of the American College of Cardiology, 57:E188–E188. Elsevier BV, 2011. https://doi.org/10.1016/s0735-1097(11)60188-5.

Brinks HL, Rohde D, Voelkers M, Qiu G, Pleger ST, Herzog N, et al. S100A1 GENETICALLY TARGETED THERAPY REVERSES DYSFUNCTION OF HUMAN FAILING MYOCARDIUM. In: Journal of the American College of Cardiology. Elsevier BV; 2011. p. E188–E188.

Brinks, Henriette L., et al. “S100A1 GENETICALLY TARGETED THERAPY REVERSES DYSFUNCTION OF HUMAN FAILING MYOCARDIUM.” Journal of the American College of Cardiology, vol. 57, no. 14, Elsevier BV, 2011, pp. E188–E188. Crossref, doi:10.1016/s0735-1097(11)60188-5.

Brinks HL, Rohde D, Voelkers M, Qiu G, Pleger ST, Herzog N, Rabinowitz J, Ruhparwar A, Silvestry S, Kraus C, Mather P, Katus HA, Koch WJ, Most P. S100A1 GENETICALLY TARGETED THERAPY REVERSES DYSFUNCTION OF HUMAN FAILING MYOCARDIUM. Journal of the American College of Cardiology. Elsevier BV; 2011. p. E188–E188.